Tandem Diabetes price target lowered to $45 from $55 at RBC Capital

RBC Capital lowered the firm’s price target on Tandem Diabetes (TNDM) to $45 from $55 and keeps an Outperform rating on the shares as part of a broader research note previewing Q1 results for Medical Devices. Q1 underlying procedure volume and capital placements trends were solid with typical seasonality at play, which should position companies under coverage to beat expectations for the quarter, while FX has moved notably to favor large-cap medical device companies with international exposure, which is not factored into consensus estimates for Q1 or 2025, the analyst tells investors in a research note. Tariff impact is likely to be clarified by several companies, though many companies under coverage have low tariff exposure with a substantial U.S. manufacturing footprint or low relative exposure vs. other large caps, the firm adds.